All In Biotech

Drug Trial Radar · NCT04982445

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

A Phase 4, Open-label, Single Arm Study to Optimize Implementation of CABENUVA for the Treatment of HIV-1, for Administration in U.S. Community-based Infusion Centers or Other Alternate Sites of Administration

Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Nov 18, 2021

Primary completion

Jan 31, 2024

Study completion Jan 31, 2024

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Jul 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GLACIER (Giving Long Acting CABENUVA in an Infusion center/ASA) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting \[LA\] plus Rilpivirine LA) intramuscular (IM) in infusion centers/ASAs in United States. In this study, the intervention is the process of using an infusion center/ASA as the location to receive the CABENUVA IM injections. The acceptability and feasibility of the IC/ASA to deliver CABENUVA IM injections will be assessed from the perspectives of the participants, HIV care providers and IC/ASA staff. In this study, Month 1 is the Baseline visit. CABENUVA is a registered trademark of ViiV Healthcare.

Conditions

  • HIV Infections

Interventions

  • CABENUVADrug

    CABENUVA will be administered IM at infusion centers/ASAs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM)Time frame: At Month 8

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Evans, Georgia

  • GSK Investigational Site

    East Lansing, Michigan

  • GSK Investigational Site

    Novi, Michigan

  • GSK Investigational Site

    Plymouth, Minnesota

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Florence, South Carolina

  • GSK Investigational Site

    Summerville, South Carolina

  • GSK Investigational Site

    West Columbia, South Carolina

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Kingwood, Texas

  • GSK Investigational Site

    North Richland Hills, Texas

  • GSK Investigational Site

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.